Canada markets open in 3 hours 23 minutes

Genocea Biosciences, Inc. (GNCA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7100-0.0100 (-0.58%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.7200
Open1.7100
Bid0.0000 x 1400
Ask0.0000 x 4000
Day's Range1.6950 - 1.7400
52 Week Range1.6500 - 4.0450
Volume93,830
Avg. Volume174,231
Market Cap97.497M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-0.8600
Earnings DateOct. 27, 2021 - Nov. 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.10
  • GlobeNewswire

    Genocea to Present at Upcoming Conferences

    CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in October. Scientific conferences: Event:AACR: Tumor Immunology and Immunotherapy – DetailsTopic:GEN-011: A neoantigen-targeted peripheral blood-derived T cell therapy that has broad neoantigen specificity and high T cell purity while avoidin

  • GlobeNewswire

    Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors

    CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Jennifer Herron, Senior Vice President & Chief Commercial Officer at ADC Therapeutics SA ("ADCT"), has joined its board of directors. “It is my great pleasure to welcome Jennifer to our board of directors,” said Chip Clark, Genocea’s President and Chief Executive Officer. "As we advance our pipeline,

  • GlobeNewswire

    Genocea to Present at Upcoming Scientific and Investor Conferences

    CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following virtual conferences in September. Scientific conferences: Event:Next Generation Cancer Vaccine Development Summit – DetailsTopic:Neoantigen selection to identify immunogenic tumor specific targets personalized to each patient’s tumor and immune systemForm